Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

Bispecific Antibodies Sales USD 5 Billion 2022

Release Date: 14 February 2023

Since the approval of the first bispecific antibody in 2009, this novel class of antibodies has taken the market up by the storm as more bispecific antibodies are entering the clinical pipeline and getting approved for a ...

Read More


Lunsumio Sales USD 3 Million In 2022

Release Date: 14 February 2023

One of Roche's most recent drugs, Lunsumio, has been approved for the treatment of relapsed or refractory follicular lymphoma. It is a first-in-class bispecific antibody that was approved in 2022 for the indication, and s...

Read More


Hemlibra Sales USD 4 Billion In 2022

Release Date: 14 February 2023

Roche’s blockbuster Hemlibra has become the global standard of care for the treatment of Hemophilia A. The drug remains one of Roche's best-selling drugs and generated over a billion dollars in revenue once more in ...

Read More


Rare Diseases Market Clinical Pipeline Forecast 2028

Release Date: 13 February 2023

Rare diseases have smaller patient bases when compared to other disease prevalent in the general population, which deters pharmaceutical companies to consider these diseases while developing new drugs. It has been estimat...

Read More


Crovalimab Shows Positive Results in Phase III Trial for Rare Life Threatening Blood Disorder

Release Date: 08 February 2023

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder wherein blood cells die prematurely and their production in impaired. The disorder affects both red and white blood cells as well as platelets, ...

Read More


Rapidly Expanding Global Bispecific Antibody Market

Release Date: 08 February 2023

The advancements in science and consequently, the treatment approaches, have significantly encouraged the growth and adoption of more modern therapies like immunotherapy. Monoclonal antibodies are one of the most successf...

Read More


Targeting LAG-3 CD223 In Cancer Immunotherapy

Release Date: 07 February 2023

The advent of immunotherapy has revolutionized the field of cancer therapy with the goal of harnessing one’s immune system and providing longer lasting cures. Among the existing immunotherapeutic approaches, immune ...

Read More


Oncolytic Virus Therapy Market Size Companies Clinical Trials Report 2028

Release Date: 07 February 2023

Oncolytic viruses are one of the most recently emerging therapeutic methods for cancer treatment. These viruses have an affinity for tumor cells and this characteristic is being widely exploited in the cancer therapy doma...

Read More


Emergence Of Anti TIGIT Antibodies Immunotherapy

Release Date: 07 February 2023

The continuous research being conducted in identifying new potential targets for cancer treatment has led to the recognition of TIGIT as a possible immune checkpoint target. Undoubtedly, one of the most prevailing achieve...

Read More


LAG-3 Emerging As Next Generation Immune Checkpoint Inhibitor Immunotherapy

Release Date: 06 February 2023

Global LAG-3 Inhibitor Market, Drug Sales, Price and Clinical Trials Insight 2028 Report highlights:

 

Need custom market research solution? We can help you with that too.